NeuroPace, Inc., a medical device company focused on improving the lives of individuals with epilepsy, has announced that an abstract from its Post-approval Study of the RNS System will be presented ...
MOUNTAIN VIEW, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- December 4, 2024 – NeuroPace, Inc. (NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today ...
MOUNTAIN VIEW, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced three-year ...
First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data ...
MOUNTAIN VIEW, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, ...
The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug-resistant focal epilepsy MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE ...
MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results